Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical use of tolerogenic dendritic cells-harmonization approach in european collaborative effort

  • Brinke, Anja ten
  • Hilkens, Catharien M. U.
  • Cools, Nathalie|||0000-0002-0459-901X
  • Geissler, Edward K.
  • Hutchinson, James A.
  • Lombardi, Giovanna
  • Lord, Phillip
  • Sawitzki, Birgit
  • Trzonkowski, Piotr
  • Ham, S. Marieke van
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The number of patients with autoimmune diseases and severe allergies and recipients of transplants increases worldwide. Currently, these patients require lifelong administration of immunomodulatory drugs. Often, these drugs are expensive and show immediate or late-occurring severe side effects. Treatment would be greatly improved by targeting the cause of autoimmunity, that is, loss of tolerance to self-antigens. Accumulating knowledge on immune mechanisms has led to the development of tolerogenic dendritic cells (tolDC), with the specific objective to restrain unwanted immune reactions in the long term. The first clinical trials with tolDC have recently been conducted and more tolDC trials are underway. Although the safety trials have been encouraging, many questions relating to tolDC, for example, cell-manufacturing protocols, administration route, amount and frequency, or mechanism of action, remain to be answered. Aiming to join efforts in translating tolDC and other tolerogenic cellular products (e.g., Tregs and macrophages) to the clinic, a European COST (European Cooperation in Science and Technology) network has been initiated-A FACTT (action to focus and accelerate cell-based tolerance-inducing therapies). A FACTT aims to minimize overlap and maximize comparison of tolDC approaches through establishment of minimum information models and consensus monitoring parameters, ensuring that progress will be in an efficient, safe, and cost-effective way.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Monitoring t-cell responses in translational studies: optimization of Dye-Based Proliferation Assay for Evaluation of Antigen-specific responses

  • Brinke, Anja ten
  • Marek-Trzonkowska, Natalia
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Turksma, Annelies W.
  • Piekarska, Karolina
  • Iwaszkiewicz-Grzes, Dorota|||0000-0003-1177-1874
  • Passerini, Laura
  • Locafaro, Grazia
  • Puñet Ortiz, Joan
  • van Ham, S. Marieke
  • Hernandez Fuentes, Maria P.
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Gregori, Silvia
Adoptive therapy with regulatory T cells or tolerance-inducing antigen (Ag)- presenting cells is innovative and promising therapeutic approach to control undesired and harmful activation of the immune system, as observed in autoimmune diseases, solid organ and bone marrow transplantation. One of the critical issues to elucidate the mechanisms responsible for success or failure of these therapies and define the specificity of the therapy is the evaluation of the Ag-specific T-cell responses. Several efforts have been made to develop suitable and reproducible assays. Here, we focus on dye-based proliferation assays. We highlight with practical examples the fundamental issues to take into consideration for implementation of an effective and sensitive dye-based proliferation assay to monitor Ag-specific responses in patients. The most critical points were used to design a road map to set up and analyze the optimal assay to assess Ag-specific T-cell responses in patients undergoing different treatments. This is the first step to optimize monitoring of tolerance induction, allowing comparison of outcomes of different clinical studies. The road map can also be applied to other therapeutic interventions, not limited to tolerance induction therapies, in which Ag-specific T-cell responses are relevant such as vaccination approaches and cancer immunotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ways forward for tolerance-inducing cellular therapies- An afactt perspective

  • Ten Brinke, Anja
  • Martinez-Llordella, Marc
  • Cools, Nathalie|||0000-0002-0459-901X
  • Hilkens, Catharien M. U.
  • van Ham, S. Marieke
  • Sawitzki, Birgit
  • Geissler, Edward K.
  • Lombardi, Giovanna
  • Trzonkowski, Piotr
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.